Welcome to our dedicated page for SMITH & NEPHEW PLC SEC filings (Ticker: SNNUF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SMITH & NEPHEW PLC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SMITH & NEPHEW PLC's regulatory disclosures and financial reporting.
Smith+Nephew reported first-half 2026 revenue of $3,097 million, up 4.6% reported and 2.3% on an underlying basis, with operating profit rising to $448 million and trading profit to $566 million, lifting the trading margin to 18.3% from 17.7%.
Earnings per share were 35.6 cents versus 33.5 cents, while adjusted EPS (EPSA) increased 11.0% to 47.7 cents. Cash generated from operations was $605 million and free cash flow $231 million. Net debt stood at $3,019 million, a leverage ratio of 1.8x, after funding higher capex and the Integrity Orthopaedics acquisition.
Sports Medicine & ENT delivered double‑digit reported growth; Advanced Wound Management was held back by reimbursement changes in skin substitutes; Orthopaedics was broadly flat underlying, with US Knee and Hip headwinds. The company cut expected full‑year underlying revenue growth from around 6% to around 4%, but still targets around 8% trading profit growth excluding acquisitions, around $800 million free cash flow and adjusted ROIC above 10%, supported by efficiency savings now expected to reach about $200 million in 2026. A $500 million share buyback is under way and the interim dividend was raised 4% to 15.6 cents per share.
Smith & Nephew plc reports its current share capital and voting rights as at 31 July 2026. Total issued share capital comprises 877,733,750 ordinary shares of US20¢ each, including 37,876,589 ordinary shares held in treasury.
Because treasury shares do not carry votes, the company’s share capital with voting rights consists of 839,857,161 ordinary shares, each with one voting right. Shareholders are directed to use 839,857,161 as the denominator when assessing whether their holdings trigger notification obligations under the FCA’s Disclosure Guidance and Transparency Rules.
In Amendment No. 8 to a Schedule 13D, Cevian Capital II GP Limited reported beneficial ownership of 119,179,419 ordinary shares of Smith & Nephew plc, representing 14.18% of the company’s ordinary shares outstanding as of July 23, 2026. Cevian has sole voting and sole dispositive power over these shares.
The Cevian Funds acquired these shares for aggregate consideration of approximately USD $1,673,390,427, funded from their general working capital. Purchases were made in British pounds, using a USD/GBP conversion rate of 1.33280 for reporting purposes, with the ownership percentage calculated on 840,515,838 ordinary shares outstanding.
Smith & Nephew plc reported a change in a major shareholding via a TR-1 notification of major holdings. Entities controlled by Cevian Capital II G.P. Limited now hold 117,912,733 voting rights in the company, representing 14.010786% of voting rights attached to shares.
This position increased from 13.206621% at the time of the previous notification. The holding is split between Cevian Capital II Master Fund L.P. with 12.815710% and Cevian Capital II Co-Investment - Series P L.P. with 1.195075%. No voting rights are held through financial instruments, and Aurora Nominees Limited is listed as the registered shareholder.
Smith+Nephew plans to announce its second quarter trading and first half 2026 results for the period ended 27 June 2026 on 4 August 2026 at 7.00am BST / 2.00am EDT. A conference call for financial analysts will follow at 11.30am BST / 6.30am EDT. The company is a global medical technology business with 17,000 employees, operating in around 100 countries, and generated annual sales of $6.2 billion in 2025.
Smith & Nephew plc discloses a TR-1 notification that an investor group controlled by Bank of America Corporation holds 3.172736% of its voting rights. This comprises 2.402237% through shares representing 20,216,881 voting rights and 0.770499% through financial instruments over 6,484,406 voting rights, for 26,701,287 voting rights in total.
The financial instruments position includes a Right to Recall over 450,000 voting rights and multiple cash-settled swap positions totaling 6,034,406 voting rights with expiration dates between 2026 and 2030.
Smith & Nephew plc reports purchases of its Smith & Nephew plc SPON ADR American Depositary Shares on the New York Stock Exchange by three senior leaders under the Company's Employee Stock Purchase Plan on 10 July 2026 at a price of $24.48 per ADS.
Deepak Nath (Chief Executive Officer) and Paul Connolly (President, Global Operations) each acquired 434.02369 ADS, while Scott Schaffner (President, Sports Medicine) acquired 256.65972 ADS. The disclosure is made in accordance with the UK Market Abuse Regulation for Persons Discharging Managerial Responsibilities and persons closely associated with them.
Smith & Nephew plc has applied to the London Stock Exchange for 150,000 ordinary shares of US20¢ each to be admitted to trading. The shares are expected to start trading on 6 July 2026.
The new shares are reserved under a block admission and will be used to settle awards made under the company’s employee share plans. Once issued, they will rank pari passu, meaning they will have the same rights, benefits, and status as the existing ordinary shares already in circulation.
Smith & Nephew plc reports its updated share capital and voting rights position as at 30 June 2026. The company has total issued share capital of 877,733,750 ordinary shares of US20¢ each, which includes 32,697,503 ordinary shares held in treasury.
Because treasury shares do not carry voting rights, the company’s share capital with voting rights consists of 845,036,247 ordinary shares, each carrying one vote. Shareholders are advised to use this figure as the denominator when assessing whether they must notify holdings or changes in holdings under the FCA’s Disclosure Guidance and Transparency Rules.
Smith & Nephew plc reports a TR-1 notification of major holdings showing that an investor group linked to Cevian Capital has increased its position in the company.
The total holding now represents 13.206621% of voting rights, equal to 111,788,454 voting rights, up from a previously notified level of 13.056468%. All voting rights are attached directly to shares, with no additional exposure through financial instruments. The holding is split between Cevian Capital II Master Fund L.P. at 12.018425% and Cevian Capital II Co-Investment - Series P L.P. at 1.188196%, both controlled by Cevian Capital II G.P. Limited.